Latest News

15th December, 2022

Thelper one of top four finalists for DNB Healthcare Prize 2022

Thelper was pre-selected as one of the top four biotech companies to compete in the finals for the 1M NOK DNB Healthcare Prize. While we didn't win the Prize, our CEO and founder, Katja Vetvik, put up an inspiring pitch to explain how Thelper's novel anti-viral therapies can potentially transform the treatment landscape for triple negative breast cancer, and other solid tumor types with high unmet needs. 

As part of the process, Katja was interviewed in a podcast hosted by Dagens Medisin, Norway's premier medical newsletter for healthcare professionals. The podcast is accessible at the following link (in Norwegian only):

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK